Korea, Republic of
Add to My Companies | Give a Referral for this Company | Print this ProfileThe latest news, announcements and press releases from Galux.
Galux announced that it has entered into a research agreement with Boehringer Ingelheim to jointly explore the application of artificial intelligence in precision protein design for therapeutic development. The goal is to evaluate how AI can be leveraged to design purpose-specific protein molecules that meet precise scientific and translational needs, where conventional approaches face limitations.
“Through this agreement, we aim to explore how AI protein design can address highly specific scientific and translational needs — challenges that often require precise and tailored molecular solutions,” said Chaok Seok, CEO of Galux. “It’s about demonstrating that AI can move beyond prediction to purposeful molecular design, creating proteins that meet clearly defined research and therapeutic goals.”
This is the News section of the company profile page for Galux on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
